Angiomax Edges Heparin on Real-World Bleeding Complications
(MedPage Today) -- Glycoprotein IIb/IIIa inhibitors a factor, according to registry findings (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 12, 2016 Category: Cardiology Source Type: news
Cath Lab Recap: More CRT Software; Bivalirudin Patent Kerfuffle
(MedPage Today) -- Interventional cardiology news to note (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - July 14, 2016 Category: Urology & Nephrology Source Type: news
Angiomax (Bivalirudin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 13, 2016 Category: Drugs & Pharmacology Source Type: news
Federal Circuit Rules for The Medicines Company in Angiomax(R) (bivalirudin) Patent Litigation
PARSIPPANY, N.J.--(Healthcare Sales & Marketing Network)--The Medicines Company announced that the U.S. Court of Appeals for the Federal Circuit Court, in an en banc review, unanimously affirmed the earlier district court ruling in The Medicines Company v.... Biopharmaceuticals, Cardiology, LitigationThe Medicines Company, Angiomax, bivalirudin, Hospira (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 12, 2016 Category: Pharmaceuticals Source Type: news
Longer Infusion Gives Bivalirudin the Upper Hand in PCI
(MedPage Today) -- Acute stent thrombosis, major bleeding rates favorable in meta-analysis (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 15, 2016 Category: Cardiology Source Type: news
PCI Quality Initiative Cuts Bivalirudin Use, Cost, and BleedingPCI Quality Initiative Cuts Bivalirudin Use, Cost, and Bleeding
"Perhaps more important, by using a risk-directed approach to coronary intervention, we were able to cut our bleeding rate nearly in half," the study author stressed. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 8, 2016 Category: Cardiology Tags: Cardiology News Source Type: news
SCAI: No Early Sex Differences For TAVR
(MedPage Today) -- Bravo 3 substudy suggests benefit for women on bivalirudin, though (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 6, 2016 Category: Cardiology Source Type: news
Morphine at Acute MI May Blunt Short-Term Antiplatelet ResponseMorphine at Acute MI May Blunt Short-Term Antiplatelet Response
"Once morphine is given, we may consider giving other IV agents that bypass the gastric emptying, such as GP IIb/IIIa inhibitors or bivalirudin," propose investigators after their prospective study. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 3, 2016 Category: Cardiology Tags: Cardiology News Source Type: news
TCT: Structural Heart Disease and PFO Closure TrialsTCT: Structural Heart Disease and PFO Closure Trials
Drs Harrington and Bhatt discuss whether transcatheter aortic valve therapy is evolving naturally or moving beyond the evidence, bivalirudin in TAVR, and PFO closure for stroke prevention. theheart.org on Medscape (Source: theHeart.org)
Source: theHeart.org - October 19, 2015 Category: Cardiology Tags: Cardiology Commentary Source Type: news
TCT: Anticoagulants Equal in Aortic Valve Replacement
(MedPage Today) -- Bivalirudin, unfractionated heparin similar for bleeding and net outcomes in BRAVO 3 (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 16, 2015 Category: Cardiology Source Type: news
BRAVO 3: Bivalirudin No Better Than Heparin in TAVRBRAVO 3: Bivalirudin No Better Than Heparin in TAVR
In BRAVO 3, the use of bivalirudin yielded no benefit over unfractionated heparin, which experts say should limit its use to a small segment of patients, such as those with heparin-induced thrombocytopenia. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 15, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
ESC Interventional Cardiology HighlightsESC Interventional Cardiology Highlights
Drs Fox and Stone review late-breaking data on bioresorbable stents, FFRCT, and bivalirudin from the European Society of Cardiology Congress. theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 11, 2015 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Sep 4 Cardiology NewsSep 4 Cardiology News
Dr John Mandrola discusses studies from ESC, including CT-FFR, post-PCI bivalirudin, ezetimibe in diabetes, high-sensitivity troponin, resistant HTN, leadless pacing, and afternoon naps. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 4, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Expensive blood thinner no more effective than cheaper drug
Stephen FellerGREAT NECK, N.Y., Sept. 2 (UPI) -- Conflicting studies on the blood-thinning drugs heparin and bivalirudin show them to have no clear benefit over one another aside from one being more expensive. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 2, 2015 Category: Consumer Health News Source Type: news
MATRIX: Is There A Benefit From Longer Bivalirudin Infusion?MATRIX: Is There A Benefit From Longer Bivalirudin Infusion?
Prolonging the infusion of bivalirudin for several hours after the completion of PCI did not reduce the composite outcome of ischemic and bleeding end points, but a nonrandomized exploratory analysis suggests the high-dose prolonged infusion may show better results. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 1, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
